Each row is an authorised trial looking for participants. The plain-language title is written by our editorial team, and underneath it you can see the original registry title — so you can check for yourself that we did not change the meaning. We cannot tell you whether you are eligible, and we do not publish the hospital name: the international registry does not carry it, and a wrong name would send you to a room where nobody expects you. For the centre and the team's contact details, open the official record.
Trials recruiting now
Every title below has been rewritten in plain language by our editorial team, with the original underneath.
Trials testing a treatment · one study
Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.
Advanced liver cancer with Child-Pugh B7 cirrhosis: namodenoson, a medicine under study
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
For: Hepatocellular Carcinoma, Cirrhosis
6 centres: Institutul Regional de Gastroenterologie si Hepatologie, Cluj-Napoca · Spitalul Clinic Judetean de Urgenta Constanta Oncology Dept, Constanța · Oncology Center "Sf. Nectarie" Medical Oncology, Craiova · and 3 more
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Observational studies · 2 studies
You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.
Observational study: how atezolizumab treatment goes in routine practice, as patients report it
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
For: Lung Cancer, Hepatocellular Carcinoma
7 centres: Spitalul Clinic de Urgenta Prof. Dr. Agrippa Ionescu, București · Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. Octavian Fodor, Cluj-Napoca · Galați · and 4 more
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
LIVER-R observational study: following patients with hepatobiliary cancers
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multi-country, multi-center, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with or without a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of regimens (durvalumab-based or otherwise) in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, treatment provider characteristics, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, time to treatment discontinuation, recurrence-free survival, and time to treatment recurrence).
For: Hepatobiliary Cancers
4 centres: București · Cluj-Napoca · Craiova · and 1 more
The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting, with at least one site in Romania. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.
Tell us what we can improve
We use optional technologies to measure usage and campaigns and improve OncoDots. You can accept, decline, or choose separately.
